CDW HOLDING LIMITED
(Incorporated in Bermuda)
SUBSCRIPTION OF SENIOR CONVERTIBLE BONDS IN A BIOTECH CO., LTD.
1. INTRODUCTION
The board of directors (the "Board") of CDW Holding Limited (the "Company" and together with its subsidiaries, the "Group") wishes to announce that its wholly-owned subsidiary, Tomoike Industrial (H.K.) Limited ("HK Tomoike"), has entered into a Senior Convertible Bonds Subscription Agreement ("Subscription Agreement") with A Biotech Co., Ltd. (the "Issuer" or "ABio") on 17 December 2021. Pursuant to the Subscription Agreement, HK Tomoike will subscribe for an aggregate principal amount of USD800,000 of unregistered convertible bonds at the Coupon Rate (as defined herein) ("Bonds") to be issued by the Issuer for an aggregate subscription consideration of USD800,000 on the terms and conditions of the Subscription Agreement (the "Proposed Subscription").
2. THE PROPOSED SUBSCRIPTION
2.1 The Salient Terms of the Proposed Subscription are summarised as follows:
Subscriber | The sole subscriber of the Bonds is HK Tomoike. HK Tomoike is |
a wholly-owned subsidiary of the Company. As at the date of this | |
Announcement, HK Tomoike holds a 48.46% shareholding in the | |
Issuer. Assuming full conversion at the Maturity Date (as defined | |
herein), HK Tomoike will hold 51.95% shareholding in the Issuer. | |
Consideration | HK Tomoike will subscribe for an aggregate principal amount of |
USD800,000 of unregistered convertible bonds at the Coupon | |
Rate (as defined herein) ("Bonds") to be issued by the Issuer for | |
an aggregate subscription consideration of USD800,000 on the | |
terms and conditions of the Subscription Agreement. Assuming | |
conversion at the Maturity Date (as defined herein), the maximum | |
amount of the Consideration will be USD800,000. | |
Issue Price | The Bonds will be issued 100% of the total face value. |
Coupon Rate | The Coupon Rate of the Bonds is one (1)% per annum higher |
than the USD best lending rate of Hongkong and Shanghai | |
Banking Corporation Limited which will be calculated quarterly. | |
The interest shall not capitalise into the principal amount of the | |
Bonds. | |
Completion | Completion of the Proposed Subscription is to take place seven |
(7) days from the satisfaction or waiver of the conditions | |
precedent listed in the Subscription Agreement. | |
Security | The Bonds are unsecured. |
Redemption | Under the Terms and Condition of the Bonds, the Issuer shall |
redeem the Bonds at their principal amount on Maturity Date (as | |
defined herein). Early redemption is not allowed. | |
Subscriber's Right to Initiate Redemption | |
At any time after Completion, the Subscriber has the right to | |
convert all or any portion of its Bonds into the Shares at any time | |
during the Conversion Period by delivering to the Issuer a notice | |
of conversion. | |
- 1 - |
Maturity Date | The maturity date of the Bonds is three (3) years from the date of | |||
issuance of the Bonds. | ||||
Conversion Price | Conversion price of KRW15,000 (approximately USD12.71 | |||
based on the exchange rate of US$1 to KRW1,180). | ||||
Conversion Price | Price Adjustment in the Event of Free Distribution, Sub-division, | |||
Adjustments | Consolidation or Reclassification of Shares | |||
If the Issuer makes a distribution of its shares without | ||||
consideration, sub-divide any of its outstanding shares, | ||||
consolidate any of its outstanding shares into a smaller number | ||||
of shares, or re-classify any of its shares into other securities of | ||||
the shares, the Conversion Price shall be adjusted so that the | ||||
Subscriber shall be entitled to receive the number of shares | ||||
which it would have held or have been entitled to receive after | ||||
the occurrence of any of the events described herein had such | ||||
conversion been exercised immediately prior to the occurrence | ||||
of such event. | ||||
Price Adjustment on Issuance of Equity Securities | ||||
If the Issuer (i) issues or sells any of its shares for a | ||||
consideration per share (net of any selling concessions, | ||||
discounts or commissions) which is less than, or (ii) issues any | ||||
options, warrants, equity securities or any securities that are | ||||
convertible into or exercisable or convertible for or that represent | ||||
the right to acquire its shares with a conversion price, exchange | ||||
price, strike price, exercise price or other relevant price less than, | ||||
or (iii) adjusts the issue price effective under sub-clause (ii) to be | ||||
less than KRW25,000, then the Conversion Price (as of a specific | ||||
Conversion Date) shall be adjusted so that: | ||||
Aggregate sum of the Issue | ||||
Price of all New Shares | ||||
Conversion Price | below KRW25,000 | |||
After Adjustment | = | x 0.6 | ||
Total Number of New | ||||
Shares below KRW25,000 | ||||
(Issued prior to conversion | ||||
date) | ||||
Transferability | The Subscriber may resell the Bonds to any third party without | |||
the consent of the Issuer prior to the Maturity Date; provided that | ||||
such resale shall not be made to fifty (50) or more purchasers | ||||
within one (1) year after the issuance of the Bonds; provided | ||||
further, such resale shall not be made where the face value of | ||||
the Bond would require to be broken up into smaller | ||||
denomination within one (1) year after the issuance of the Bonds. | ||||
Applicable Law | Korean Law | |||
- 2 -
The Consideration was arrived based on willing-buyer and willing-seller basis taking into account various factors including, an independent valuation conducted by an independent valuer, the issue price of the ABio shares, and benchmarked against previous consideration prices of share transfers by ABio as well as against valuation of companies which are listed and traded on stock exchanges whose business activities and industries which are broadly comparable to ABio. The Consideration will be satisfied in cash.
For the purposes of the Proposed Subscription, HK Tomoike appointed Accounting Corporation Seil One of Korea as the independent valuer to conduct a stock valuation of ABio as of 30 June 2021. The valuation is prepared and based on the revenue approach using the discounted cash flow method. The discounted cash flow method is a method used to estimate the value of an investment based on its expected future cash flows. It was noted that the conversion price is at a discount range of between 64% and 66% from the equity value per share as indicated by the independent valuation.
-
Information on the Issuer
The Issuer was incorporated by HK Tomoike as a wholly owned subsidiary in South Korea on 16 January 2018. It is a research and development company with focus in the life science industry. As at the date of this Announcement, the Issuer is 48.46% owned by HK Tomoike, 27.69% owned by Mr Yoshimi Koichi and 23.85% owned by other shareholders. The Issuer is now an associated company of the Group. The directors of the Issuer are Mr Yoshimi Kunikazu, Mr Chou Li Sheng, Mr Yoshimi Koichi and Mr Kato Tomonori as at the date of this Announcement.
Based on its audited accounts for the financial year ended 31 December 2020 and the exchange rate of US$1 to KRW1,180, the Issuer incurred a loss after tax of KRW1.36 Billion, (equivalent to US$1.16 million), and had net tangible liabilities of KRW0.92 billion, (equivalent to US$0.78 million), as at 31 December 2020. - Use of Proceeds by the Issuer
The Issuer intends to use the proceeds from the Proposed Subscription as (i) working capital to fund in-house research and development activities, and daily operations; and (ii) to repay previous interest-free loans from the management of Issuer amount to KRW350 million (approximately USD 0.3 million). - Rationale and Benefit
Since July 2019, the Group has been collaborating with ABio and Okayama University on research to enhance the potential therapeutic applications of the anti-Crypto-1 antibody in targeting cancer stem cells. It is believed that the development of anti-Cripto-1 antibody in targeting cancer stem cells has the potential to bring new drugs to market with greater efficacy in the treatment of metastatic and invasive cancers.
Further pre-clinical trials will have to be completed to determine the efficacy in treating human patients. Currently, the internal trials of anti-Cripto-1 antibody against brain tumour cells have been completed, and parties are preparing to move towards the pre-clinical trials of other cancers besides brain tumour.
If the Issuer raises funding from third party investors, the Company's equity interest in the Issuer would be diluted and reduced. The Proposed Subscription allows the Company to maintain its shareholding percentage in ABio without being diluted further.
The Group currently has investible funds which has been making a return of less than 1% per annum and noted that the Proposed Subscription will generate a return of 3.5% per annum in the form of interest income to the Group. - 3 -
3. DISCLOSEABLE TRANSACTION
3.1 Relative Figures for the Proposed Subscription
3.1.1 The relative figures of the Proposed Subscription computed on the bases set out under Rule
1006 of the Listing Manual of the Singapore Exchange Securities Trading Limited ("Listing Manual") are set out below:
Rule | Bases | Relative Figures (%) | ||||||
1006 | ||||||||
(a) | The net asset value of the assets to be disposed of, | |||||||
compared with the Group's net asset value. This basis is not | Not Applicable (1) | |||||||
applicable to an acquisition of assets. | ||||||||
(b) | The net loss (2) attributable to the assets acquired or disposed | (6.52)% (3) | ||||||
of, compared with the Group's net profits (2). | ||||||||
(c) | The aggregate value of the consideration given or received, | |||||||
compared with the issuer's market capitalisation based on | 1.94% (4) | |||||||
the total number of issued shares excluding treasury shares. | ||||||||
(d) | The number of equity securities issued by the issuer as | |||||||
consideration for an acquisition, compared with the number | Not Applicable (5) | |||||||
of equity securities previously in issue. | ||||||||
(e) | The aggregate volume or amount of proved and probable | |||||||
reserves to be disposed of, compared with the aggregate of | ||||||||
the group's proved and probable reserves. This basis is | Not Applicable (6) | |||||||
applicable to a disposal of mineral, oil or gas assets by a | ||||||||
mineral, oil and gas company, but not to an acquisition of | ||||||||
such assets. | ||||||||
Notes:-
- This basis is not applicable to the Proposed Subscription.
- Under Rule 1002(3)(b), "net profits" means profit or loss before income tax, minority interests and extraordinary items, and "net loss" means the loss before income tax, minority interests and extraordinary items.
- The net loss of the Group for the six months ended 30 June 2021 is US$365,000. The net loss of ABio for the six months ended 30 June 2021 is KRW387.4 million or approximately US$328,000 based on the exchange rate of US$1 to KRW1,180. As at the date of this Announcement, ABio has issued a total of 866,665 shares. Assuming full conversion at the Maturity Date at KRW15,000 and based on the exchange rate of US$1 to KRW1,180, ABio will issue 62,933 new shares to HK Tomoike. The net loss attributable to the assets acquired would be US$23,800, being the loss of US$328,000 for the six months ended 30 June 2021 divided by the total of 866,665 shares and then multiplied by 62,933 shares.
- The Company's market capitalisation was approximately SG$56,371,000, determined by multiplying the total issued shares of 222,987,408 shares by the 6-month volume weighted average price of the Company's shares of SG$0.2528 per share, based on trades done on the SGX-ST on date of day immediately before announcement, the full market day immediately prior to the execution of the Subscription Agreement and the exchange rate of US$1 to S$1.3667 with reference to the exchange rate as quoted in Monetary Authority of Singapore on date of day immediately before announcement. The Consideration for the Proposed Subscription is SG$1,093,360 as at the date of execution of the Subscription Agreement.
- This basis is not applicable to the Proposed Subscription.
- This basis is not applicable to the Proposed Subscription.
- 4 -
3.1.2 Based on the relative figure(s) above which are computed based on the relevant bases, under Rule 1006, and taking into consideration the guidance provided in Paragraph 4.4(a) of Practice Note 10.1 of the Listing Manual, the Proposed Subscription qualifies as a discloseable transaction and is not subject to the approval of the shareholders.
3.2 Financial Effects of the Proposed Subscription
3.2.1 For illustrative purposes only, the financial effects of the Proposed Subscription on the Group based on the audited financial statements of the Group for the financial year ended 31 December 2020 are as set out below, assuming full conversion of the Bonds had been exercised and conversion shares issued as at the beginning of FY2020. Please note that the financial effects of the Proposed Subscription on the Group as set out above are strictly for illustrative purposes only and do not purport to be indicative or a projection of the results and financial position of the Company and the Group after the Proposed Subscription. No representation is made as to the actual financial position and/or results of the Company and the Group after completion of the Proposed Subscription.
-
Earnings Per Share ("EPS")
The effect of the Proposed Subscription on the EPS of the Group shown below is based on the most recently completed financial year (i.e. FY2020), assuming that the Proposed Subscription had been effected at the beginning of FY2020.
Before the Proposed | After the Proposed | |
Subscription, | Subscription, | |
conversion and issue of | conversion and issue of | |
conversion shares | conversion shares | |
Profit attributable to | 1,474,000 | 1,452,000 |
owners of the Company | ||
(US$) | ||
Weighted average | 222,115,116 | 222,115,116 |
number of issued shares | ||
EPS (US cents) | 0.66 | 0.65 |
- Net Tangible Assets ("NTA") per share
The effect of the Proposed Subscription on the NTA per share of the Group shown below is based on the most recently completed financial year (i.e. FY2020), assuming that the Proposed Subscription, full conversion of the Bonds had been exercised and conversion shares issued as at the end of FY2020.
Before the Proposed | After the Proposed | |
Subscription, | Subscription, | |
conversion and issue of | conversion and issue of | |
conversion shares | conversion shares | |
NTA (US$) | 50,002,000 | 49,757,000 |
Number of issued shares | 221,987,408 | 221,987,408 |
NTA per share (US cents) | 22.52 | 22.41 |
3.3 Source of Funds for the Bonds
The Consideration will be satisfied in cash which will be funded by internal resources.
- 5 -
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
CDW Holding Limited published this content on 17 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 December 2021 10:18:04 UTC.